 Brooks Hybertson
Concepts (198)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| NF-E2-Related Factor 2 | 6 | 2022 | 76 | 1.490 |
Why?
| | Interleukin-1 | 15 | 2003 | 972 | 0.920 |
Why?
| | Lung | 20 | 2005 | 3925 | 0.730 |
Why?
| | Neutrophils | 18 | 2005 | 1203 | 0.670 |
Why?
| | Oxidative Stress | 6 | 2019 | 1220 | 0.470 |
Why?
| | Health | 1 | 2014 | 74 | 0.450 |
Why?
| | Disease | 1 | 2014 | 95 | 0.430 |
Why?
| | Xanthine Oxidase | 4 | 2002 | 79 | 0.400 |
Why?
| | Chemokines, CXC | 7 | 2005 | 69 | 0.380 |
Why?
| | Chemotactic Factors | 6 | 1997 | 55 | 0.340 |
Why?
| | Intercellular Signaling Peptides and Proteins | 7 | 2005 | 376 | 0.330 |
Why?
| | Rats | 26 | 2006 | 5236 | 0.320 |
Why?
| | Ferritins | 3 | 2004 | 58 | 0.310 |
Why?
| | Antioxidants | 3 | 2019 | 557 | 0.310 |
Why?
| | Rats, Sprague-Dawley | 22 | 2006 | 2308 | 0.310 |
Why?
| | Vitamin E | 2 | 1998 | 118 | 0.260 |
Why?
| | alpha-Tocopherol | 1 | 2005 | 32 | 0.240 |
Why?
| | Signal Transduction | 3 | 2019 | 4857 | 0.230 |
Why?
| | Pneumonia | 3 | 2005 | 612 | 0.200 |
Why?
| | Deferoxamine | 1 | 2002 | 20 | 0.200 |
Why?
| | Iron Chelating Agents | 1 | 2002 | 17 | 0.200 |
Why?
| | Animals | 32 | 2022 | 34628 | 0.200 |
Why?
| | Proteostasis | 1 | 2022 | 26 | 0.200 |
Why?
| | Growth Substances | 5 | 1997 | 155 | 0.190 |
Why?
| | Lipopolysaccharides | 1 | 2005 | 877 | 0.190 |
Why?
| | Bronchoalveolar Lavage Fluid | 10 | 2005 | 642 | 0.180 |
Why?
| | Transforming Growth Factor beta | 1 | 2003 | 460 | 0.180 |
Why?
| | Cistaceae | 1 | 2020 | 1 | 0.180 |
Why?
| | Pentoxifylline | 2 | 1997 | 24 | 0.170 |
Why?
| | Isoniazid | 3 | 2006 | 59 | 0.170 |
Why?
| | Macrophages, Alveolar | 4 | 2006 | 389 | 0.170 |
Why?
| | tat Gene Products, Human Immunodeficiency Virus | 1 | 2019 | 22 | 0.160 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2005 | 1204 | 0.160 |
Why?
| | Antioxidant Response Elements | 2 | 2019 | 6 | 0.160 |
Why?
| | Peroxidase | 8 | 2003 | 183 | 0.160 |
Why?
| | Oxidants | 2 | 2004 | 109 | 0.150 |
Why?
| | Lung Injury | 3 | 1996 | 214 | 0.150 |
Why?
| | Alveolar Epithelial Cells | 1 | 2019 | 106 | 0.150 |
Why?
| | Pulmonary Alveoli | 1 | 2000 | 403 | 0.140 |
Why?
| | Neutropenia | 1 | 1997 | 135 | 0.140 |
Why?
| | Nitric Oxide | 3 | 1997 | 892 | 0.140 |
Why?
| | Edema | 1 | 1997 | 127 | 0.140 |
Why?
| | Altitude | 1 | 2020 | 451 | 0.130 |
Why?
| | Adjuvants, Immunologic | 1 | 1997 | 219 | 0.120 |
Why?
| | Vitamin E Deficiency | 1 | 1995 | 43 | 0.120 |
Why?
| | Chemokine CXCL1 | 5 | 2005 | 75 | 0.120 |
Why?
| | HIV Infections | 2 | 2019 | 2696 | 0.120 |
Why?
| | Trachea | 5 | 2005 | 228 | 0.110 |
Why?
| | Drug Delivery Systems | 3 | 2005 | 328 | 0.110 |
Why?
| | Perfusion | 5 | 2002 | 191 | 0.100 |
Why?
| | HIV-1 | 1 | 2019 | 840 | 0.100 |
Why?
| | Recombinant Proteins | 6 | 2005 | 1304 | 0.100 |
Why?
| | MicroRNAs | 1 | 2019 | 668 | 0.100 |
Why?
| | Antitubercular Agents | 2 | 2005 | 195 | 0.100 |
Why?
| | Drugs, Chinese Herbal | 1 | 2011 | 13 | 0.100 |
Why?
| | Quinacrine | 2 | 2004 | 9 | 0.090 |
Why?
| | Platelet Activating Factor | 2 | 2002 | 75 | 0.090 |
Why?
| | Leukocyte Count | 3 | 2003 | 328 | 0.090 |
Why?
| | Permeability | 3 | 2002 | 158 | 0.090 |
Why?
| | Circadian Rhythm | 1 | 2014 | 401 | 0.090 |
Why?
| | Oxidation-Reduction | 4 | 2019 | 1013 | 0.090 |
Why?
| | Tissue Plasminogen Activator | 2 | 2005 | 225 | 0.090 |
Why?
| | In Vitro Techniques | 4 | 2002 | 1061 | 0.090 |
Why?
| | Capillary Permeability | 4 | 2002 | 141 | 0.080 |
Why?
| | Hemorrhage | 2 | 2004 | 658 | 0.080 |
Why?
| | Indicators and Reagents | 3 | 2000 | 108 | 0.080 |
Why?
| | Purines | 2 | 2002 | 170 | 0.080 |
Why?
| | Cells, Cultured | 4 | 2019 | 4048 | 0.080 |
Why?
| | Administration, Inhalation | 4 | 2005 | 675 | 0.080 |
Why?
| | Enzyme Inhibitors | 2 | 2004 | 827 | 0.070 |
Why?
| | Male | 22 | 2022 | 63146 | 0.070 |
Why?
| | Therapeutic Irrigation | 2 | 1997 | 74 | 0.070 |
Why?
| | Reactive Oxygen Species | 3 | 2019 | 575 | 0.070 |
Why?
| | Oxygen | 2 | 2003 | 912 | 0.070 |
Why?
| | Hydrogen Peroxide | 4 | 2002 | 310 | 0.060 |
Why?
| | Aerosols | 2 | 1998 | 172 | 0.060 |
Why?
| | Mitochondria | 2 | 2022 | 837 | 0.060 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2006 | 484 | 0.060 |
Why?
| | Cell Line | 4 | 2019 | 2759 | 0.060 |
Why?
| | Tandem Mass Spectrometry | 1 | 2006 | 441 | 0.060 |
Why?
| | Genetic Therapy | 1 | 2005 | 292 | 0.050 |
Why?
| | Pulmonary Circulation | 1 | 2005 | 429 | 0.050 |
Why?
| | Microspheres | 1 | 2003 | 123 | 0.050 |
Why?
| | Polyesters | 1 | 2003 | 72 | 0.050 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2003 | 173 | 0.050 |
Why?
| | Intercellular Junctions | 1 | 2002 | 39 | 0.050 |
Why?
| | Thiobarbituric Acid Reactive Substances | 1 | 2002 | 23 | 0.050 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2003 | 58 | 0.050 |
Why?
| | Humans | 14 | 2021 | 128896 | 0.050 |
Why?
| | Intubation, Intratracheal | 3 | 2002 | 241 | 0.050 |
Why?
| | Guinea Pigs | 1 | 2022 | 158 | 0.050 |
Why?
| | Prodrugs | 1 | 2002 | 49 | 0.050 |
Why?
| | Superoxides | 2 | 1999 | 200 | 0.050 |
Why?
| | Nitroblue Tetrazolium | 2 | 2000 | 12 | 0.050 |
Why?
| | Phospholipids | 2 | 2000 | 209 | 0.050 |
Why?
| | Inflammation | 1 | 2011 | 2694 | 0.040 |
Why?
| | Phytochemicals | 1 | 2020 | 13 | 0.040 |
Why?
| | Iron | 1 | 2002 | 285 | 0.040 |
Why?
| | Bronchoalveolar Lavage | 2 | 1998 | 92 | 0.040 |
Why?
| | Diet | 2 | 2020 | 1205 | 0.040 |
Why?
| | Organ Size | 2 | 1998 | 446 | 0.040 |
Why?
| | Microscopy, Electron | 1 | 2000 | 417 | 0.040 |
Why?
| | Endothelium | 2 | 1997 | 114 | 0.040 |
Why?
| | Pulmonary Surfactants | 1 | 2000 | 108 | 0.040 |
Why?
| | Oxidoreductases Acting on Sulfur Group Donors | 1 | 2019 | 11 | 0.040 |
Why?
| | Rats, Transgenic | 1 | 2019 | 15 | 0.040 |
Why?
| | Antagomirs | 1 | 2019 | 13 | 0.040 |
Why?
| | NAD(P)H Dehydrogenase (Quinone) | 1 | 2019 | 31 | 0.040 |
Why?
| | Pulmonary Edema | 2 | 1997 | 105 | 0.040 |
Why?
| | Heme Oxygenase-1 | 1 | 2019 | 62 | 0.040 |
Why?
| | Rats, Inbred F344 | 1 | 2019 | 251 | 0.040 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2000 | 199 | 0.040 |
Why?
| | Plant Extracts | 1 | 2020 | 179 | 0.040 |
Why?
| | Receptors, Cell Surface | 1 | 2000 | 379 | 0.040 |
Why?
| | Endothelium, Vascular | 2 | 2002 | 917 | 0.040 |
Why?
| | Phosphatidic Acids | 1 | 1997 | 9 | 0.040 |
Why?
| | HIV | 1 | 2019 | 223 | 0.040 |
Why?
| | Alprostadil | 1 | 1997 | 32 | 0.040 |
Why?
| | Vinblastine | 1 | 1997 | 69 | 0.040 |
Why?
| | RNA, Messenger | 1 | 2005 | 2700 | 0.040 |
Why?
| | Cattle | 2 | 1997 | 970 | 0.040 |
Why?
| | Chemotaxis, Leukocyte | 1 | 1997 | 137 | 0.040 |
Why?
| | RNA, Small Interfering | 1 | 2019 | 575 | 0.030 |
Why?
| | Phospholipases A | 1 | 1997 | 100 | 0.030 |
Why?
| | Luminescent Measurements | 1 | 1997 | 78 | 0.030 |
Why?
| | Drug Carriers | 1 | 1997 | 115 | 0.030 |
Why?
| | Neutrophil Activation | 1 | 1997 | 79 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2003 | 1359 | 0.030 |
Why?
| | Liposomes | 1 | 1997 | 163 | 0.030 |
Why?
| | Particle Size | 1 | 1998 | 351 | 0.030 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 1997 | 151 | 0.030 |
Why?
| | Carrier Proteins | 2 | 1997 | 728 | 0.030 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 1996 | 163 | 0.030 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 348 | 0.030 |
Why?
| | Disease Models, Animal | 4 | 2019 | 3994 | 0.030 |
Why?
| | Pulmonary Artery | 3 | 1997 | 1091 | 0.030 |
Why?
| | Free Radicals | 1 | 1995 | 102 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2019 | 734 | 0.030 |
Why?
| | Chemistry, Pharmaceutical | 2 | 2005 | 104 | 0.030 |
Why?
| | Lung Diseases | 1 | 2000 | 755 | 0.030 |
Why?
| | Respiration, Artificial | 1 | 1997 | 594 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 1996 | 503 | 0.030 |
Why?
| | Acetylcysteine | 1 | 1993 | 148 | 0.030 |
Why?
| | Muscle, Skeletal | 1 | 2022 | 1629 | 0.020 |
Why?
| | Kidney | 1 | 1999 | 1330 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 1996 | 1694 | 0.020 |
Why?
| | Aging | 1 | 2022 | 1767 | 0.020 |
Why?
| | Azepines | 2 | 2002 | 87 | 0.020 |
Why?
| | Models, Biological | 1 | 1997 | 1702 | 0.020 |
Why?
| | Triazoles | 2 | 2002 | 153 | 0.020 |
Why?
| | Cell Count | 2 | 2002 | 316 | 0.020 |
Why?
| | Cell Adhesion | 2 | 2000 | 452 | 0.020 |
Why?
| | N-Formylmethionine Leucyl-Phenylalanine | 2 | 1997 | 55 | 0.020 |
Why?
| | Enzyme Stability | 1 | 2005 | 68 | 0.020 |
Why?
| | Molecular Structure | 1 | 2006 | 469 | 0.020 |
Why?
| | Microscopy, Electron, Scanning | 1 | 2005 | 194 | 0.020 |
Why?
| | Drug Compounding | 1 | 2005 | 97 | 0.020 |
Why?
| | Pulmonary Ventilation | 1 | 2005 | 77 | 0.020 |
Why?
| | Delayed-Action Preparations | 1 | 2005 | 178 | 0.010 |
Why?
| | Nanostructures | 1 | 2005 | 98 | 0.010 |
Why?
| | Iron, Dietary | 1 | 2003 | 21 | 0.010 |
Why?
| | Crystallization | 1 | 2003 | 136 | 0.010 |
Why?
| | Leukocytes | 1 | 2004 | 301 | 0.010 |
Why?
| | Fibrinolytic Agents | 1 | 2005 | 264 | 0.010 |
Why?
| | Mass Spectrometry | 1 | 2005 | 659 | 0.010 |
Why?
| | Ions | 1 | 2002 | 66 | 0.010 |
Why?
| | Quaternary Ammonium Compounds | 1 | 2002 | 52 | 0.010 |
Why?
| | Aged | 1 | 2021 | 22035 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2005 | 859 | 0.010 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 1 | 2002 | 183 | 0.010 |
Why?
| | Platelet Membrane Glycoproteins | 1 | 2000 | 35 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2006 | 3042 | 0.010 |
Why?
| | Instillation, Drug | 1 | 1998 | 10 | 0.010 |
Why?
| | Hyperoxia | 1 | 1999 | 97 | 0.010 |
Why?
| | NF-kappa B | 1 | 2002 | 685 | 0.010 |
Why?
| | Injections, Intraperitoneal | 1 | 1998 | 106 | 0.010 |
Why?
| | Linoleic Acid | 1 | 1997 | 41 | 0.010 |
Why?
| | Oleic Acid | 1 | 1997 | 38 | 0.010 |
Why?
| | Phospholipases A2 | 1 | 1997 | 80 | 0.010 |
Why?
| | Tumor Necrosis Factor Decoy Receptors | 1 | 1996 | 8 | 0.010 |
Why?
| | Arginine | 1 | 1998 | 254 | 0.010 |
Why?
| | Interleukin-8 | 1 | 1997 | 261 | 0.010 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 1996 | 85 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 1998 | 760 | 0.010 |
Why?
| | Injections | 1 | 1996 | 174 | 0.010 |
Why?
| | Injections, Spinal | 1 | 1995 | 106 | 0.010 |
Why?
| | Female | 1 | 2022 | 68162 | 0.010 |
Why?
| | Glutathione Disulfide | 1 | 1993 | 32 | 0.010 |
Why?
| | Acute Disease | 1 | 1996 | 978 | 0.010 |
Why?
| | Respiration | 1 | 1993 | 191 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1997 | 1968 | 0.010 |
Why?
| | Adult | 1 | 1995 | 35361 | 0.010 |
Why?
| | Glutathione | 1 | 1993 | 333 | 0.010 |
Why?
| | Cell Movement | 1 | 1996 | 932 | 0.010 |
Why?
| | Proteins | 1 | 1997 | 945 | 0.010 |
Why?
| | Immunoglobulin G | 1 | 1995 | 834 | 0.010 |
Why?
| | Time Factors | 1 | 2000 | 6568 | 0.010 |
Why?
| | Blood Pressure | 1 | 1995 | 1743 | 0.000 |
Why?
|
|
Hybertson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|